UNITED STATES ~~SECURITIES AND EXCHANGE COMMISSION~~

~~Washington,~~SECURITIES ~~D.C.~~AND ~~20549~~EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

~~REPORT~~Report OFof ~~FOREIGN~~Foreign ~~PRIVATE~~Private ~~ISSUER~~Issuer ~~PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934~~

~~For~~Pursuant ~~the~~to ~~Month~~Rule of13a-16 ~~October~~or ~~2021~~15d-16

under the Securities Exchange Act of 1934

For the month of October 2021

Commission File Number 001-38775

ITAMAR MEDICAL LTD.

(Translation of ~~registrant~~Registrant’s name into English)

9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive ~~office~~offices)

Indicate by check mark whether the ~~registrant~~ Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.:

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

~~Note:~~Information ~~Regulation~~Contained ~~S-T Rule 101(b)(7) only permits the submission~~ in ~~paper~~this ofReport a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K ~~submission or other Commission filing on EDGAR.~~

~~Indicate~~On bySeptember ~~check~~13, ~~mark~~2021, ~~whether~~Itamar ~~the~~Medical ~~registrant~~Ltd. (“Itamar”, bythe ~~furnishing~~“Company”, “we”, or the ~~information~~“Registrant”) ~~contained~~announced inthat ~~this~~it ~~Form~~has isentered ~~also~~into ~~thereby~~an ~~furnishing~~Agreement ~~the~~and ~~information~~Plan of toMerger, dated as of even date (the ~~Commission~~“Merger ~~pursuant~~Agreement”), towith ~~Rule~~ZOLL ~~12g3-2~~Medical Corporation, a Massachusetts corporation (b“Parent”) and a subsidiary of Asahi Kasei Corporation (“Guarantor”), Zeus Merger Sub Ltd., a company organized under the ~~Securities~~laws ~~Exchange~~of ~~Act~~the State of ~~1934~~Israel (“Merger Sub”) and a wholly owned subsidiary of Parent, and, solely for purposes of certain specified provisions of the Merger Agreement, Guarantor, whereby, among other things, Merger Sub will merge with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the “Merger”).

~~Yes~~As ~~¨ No~~previously ¨reported, the closing of the transactions contemplated by the Merger Agreement is conditioned upon, among other things, the expiration of any applicable waiting period of the Hart-Scott-Rodino Antitrust Improvement Acts of 1976, as amended (the “HSR Act”) and waiver, clearance or affirmative approval of the Israeli Competition Authority (the “ICA”) under the Israeli Economic Competition Law-1988 (the “Israeli Competition Law”), relating to the consummation of the Merger.

IfThe ~~“Yes”~~Company ishereby ~~marked~~reports that the applicable waiting period under the HSR Act expired as of 11:59 p.m. EST on October 27, ~~indicate~~2021, ~~below~~and that the ICA granted the requisite affirmative ~~file~~approval ~~number~~on ~~assigned~~October 25, 2021. The completion of the Merger remains subject to other customary closing conditions, including the ~~registrant~~approval of inthe ~~connection~~Merger ~~with~~Agreement ~~Rule~~by ~~12g3-2(b):~~Itamar ~~82-~~shareholders.

_This report on Form 6-K is furnished with the Securities and Exchange Commission. This report shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.

~~This~~Cautionary ~~Form~~Statement ~~6-K,~~Regarding ~~including the exhibits hereto, is being incorporated by reference into the Registrant’s Form F~~Forward-3Looking ~~Registration~~ Statements ~~File Nos. 333-252364 and 333-250155 and Form S-8 Registration Statements File Nos. 333-236883 and 333-230799.~~

~~EXPLANATORY~~This ~~NOTE~~communication contains certain information which may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements relate to future events that are based on current expectations, estimates, forecasts and projections. These statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. All statements other than statements of historical fact or relating to present facts or current conditions included in this communication are forward-looking statements. Such forward-looking statements include, among others, Itamar’s current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. Forward-looking statements can usually be identified by the use of terminology such as “anticipate,” “believe,” “could,” “continue,” “estimate,” “expect,” “goals,” “intend,” “likely,” “may,” “might,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would,” and variations of such words and similar expressions. Those risks, uncertainties and assumptions include, (i) the risk that the proposed transaction may not be completed in a timely manner or at all, which may adversely affect Itamar’s business and the price of the ordinary shares and American Depositary Shares of Itamar, (ii) the failure to satisfy any of the conditions to the consummation of the proposed transaction, including the approval thereof by the shareholders of Itamar, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) the effect of the announcement or pendency of the proposed transaction on Itamar’s business relationships, operating results and business generally, (v) risks that the proposed transaction disrupts current plans and operations and the potential difficulties in employee retention as a result of the proposed transaction, (vi) risks related to diverting management’s attention from Itamar’s ongoing business operations, (vii) the outcome of any legal proceedings that may be instituted against Itamar related to the merger agreement or the proposed transaction, (viii) unexpected costs, charges or expenses resulting from the proposed transaction, and (ix) other risks described in Itamar’s filings with the Securities and Exchange Commission (“SEC”), such as its Annual Report on Form 20-F filed with the SEC on March 29, 2021 and the Proxy Statement on Form 6-K furnished to the SEC on October 14, 2021.

~~On October~~Any ~~12,~~forward-looking ~~2021,~~statement ~~Itamar~~made ~~Medical~~in ~~Ltd.~~this ~~(the~~communication speaks ~~“Company”)~~only ~~announced~~as ~~that it will hold its Special and 2021 Annual General Meeting~~ of ~~Shareholders (~~the ~~“Meeting”)~~date on ~~Tuesday,~~which ~~November~~it ~~16,~~is ~~2021~~made. atYou ~~1:00~~should PMnot ~~(Israel~~put ~~time)~~undue ~~(6:00~~reliance AMon ~~Eastern~~any ~~time), as~~forward-looking ~~set~~statements. ~~forth~~Itamar inundertakes no ~~the~~obligation, ~~notice~~and ofexpressly ~~the~~disclaims ~~Meeting~~any ~~(the~~obligation, ~~“Notice”) that was attached as Exhibit 99.1~~ to ~~the~~update, ~~Company’s~~alter ~~Report~~or ofotherwise ~~Foreign~~revise ~~Private~~any ~~Issuer on Form 6~~forward-Klooking statement, ~~furnished~~whether ~~to the Securities and Exchange Commission~~written ~~(the~~or ~~“SEC”)~~oral, onthat ~~the~~may ~~same~~be ~~day.~~made Asfrom ~~contemplated~~time byto ~~the Notice~~time, ~~the~~whether ~~Company~~as ~~hereby~~a ~~furnishes~~result ~~copies~~ of ~~the~~new ~~Company’s proxy statement~~information, ~~which~~future ~~includes~~developments ~~the~~or ~~Notice~~otherwise, ~~(“Proxy~~except ~~Statement”)~~ as ~~well~~may asbe required ~~proxy~~by ~~card for the Meeting~~law. ~~Copies~~If ofwe ~~the Proxy~~do ~~Statement,~~update ~~form~~one ofor ~~proxy~~more ~~card~~forward-looking ~~and~~statements, ~~voting~~no ~~instructions~~inference ~~form~~should ~~for~~be ~~use~~drawn bythat ~~holders~~we ofwill ~~the~~make ~~Company’s~~additional ~~American Depositary Shares~~updates ~~are~~with ~~attached~~respect to ~~this~~those ~~Form~~or 6other forward-Klooking ~~as exhibits 99~~statements.~~1, 99.2 and 99.3, respectively, and incorporated herein by reference.~~

This Form 6-K is incorporated by reference into the registration statements on Form F-3 (File No.333-252364 and 333-250155) and on Form S-8 (File No. 333-236883 and 333-230799), of the Company, filed with the SEC, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Additional Information and Where to Find It

This communication is being made in respect of the proposed transaction involving Itamar and Parent. In connection with the proposed transaction, Itamar has furnished to the SEC a proxy statement regarding the proposed transaction. Itamar may also furnish or file other documents with the SEC regarding the proposed transaction. This communication is not a substitute for the proxy statement or any other document that may be furnished or filed by Itamar with the SEC. BEFORE MAKING ANY VOTING DECISION, ITAMAR’S SHAREHOLDERS ARE URGED TO READ THE PROXY STATEMENT IN ITS ENTIRETY AND ANY OTHER DOCUMENTS FURNISHED OR FILED BY ITAMAR WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE THEREIN BEFORE MAKING ANY VOTING OR INVESTMENT DECISION WITH RESPECT TO THE PROPOSED TRANSACTION BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION. Investors and shareholders may obtain a free copy of the proxy statement and other documents Itamar furnishes or files with the SEC (when available) through the website maintained by the SEC at www.sec.gov, at Itamar’s Investor Relations website at ir.itamar-medical.com or by writing to Itamar, 9 Halamish Street, Caesarea 3079883, Israel, investors@itamar-medical.com.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the ~~registrant~~Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ITAMAR MEDICAL LTD.

By:	/s/ Shy Basson
	Shy Basson
	Chief Financial Officer

Date: October 1429, 2021

Exhibit Index

Exhibit 99.1	Proxy Statement for the Company’s Special and 2021 Annual General Meeting to be held on November 16, 2021.
Exhibit 99.2	Form of Proxy Card to be used in connection with the Company’s Special and 2021 Annual General Meeting to be held on November 16, 2021.
Exhibit 99.3	Form of Voting Instructions to be used by the holders of American Depositary Shares of the Company in connection with the Company’s Special and 2021 Annual General Meeting to be held on November 16, 2021.

Filing Compare · Itamar Medical Ltd.